Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders
Chronic kidney disease
Diabetes devices & technology
GLP-1 receptor agonists
Hyperglycemia
Hypoglycemia
Obesity, diet, & lifestyle interventions
SGLT2 inhibitors
Type 1 diabetes
Type 2 diabetes
Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring
Fasting for religion and health in people with diabetes
The challenge of type 2 diabetes in children
HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved
Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice
The SURPASS trials: Summarizing efficacy data on tirzepatide
Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials
Why psychosocial care matters
DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022
The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
Log in

06-27-2021 | ADA 2021 | Conference coverage | Video

SURPASS-3: Tirzepatide versus insulin degludec in type 2 diabetes

Francesco Giorgino discusses the advantages of tirzepatide over insulin degludec revealed in the SURPASS-3 findings for people requiring an injectable therapy for type 2 diabetes (6:00).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

06-26-2021 | ADA 2021 | Conference coverage | News

Tirzepatide has efficacy edge over semaglutide in SURPASS-2

10-14-2020 | Tirzepatide | At a glance | Article

A quick guide to the SURPASS and SURMOUNT trials
Phase 3 and 4 trials of tirzepatide in type 2 diabetes and obesity

10-14-2020 | Type 2 diabetes | Editorial | Article

Tirzepatide: A new challenger for type 2 diabetes management?

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video
Image Credits